Vijayakrishna Gadi, MD, University of Illinois College of Medicine

Articles

Using Systemic Therapy to Treat HER2+ Breast Cancer

August 24th 2021

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Emerging Therapies for HER2+ MBC

August 24th 2021

An overview of therapies under study in later-stage clinical trials to treat HER2-positive metastatic breast cancer.

Immunotherapy for HER2+ Breast Cancer

August 24th 2021

The rationale for incorporating checkpoint inhibitors into treatment regimens for HER2-positive breast cancer.

Emerging Combinations for Triple-Positive Breast Cancer

August 17th 2021

An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.

Frontline Therapy for Triple-Positive Breast Cancer

August 17th 2021

Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.

Gaps in Treatment for HER2+ MBC With Brain Metastasis

August 10th 2021

Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.

Case Scenario: 55-Year-Old Woman With HER2+ MBC and Brain Metastasis

August 10th 2021

A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.

Treatment Options for HER2+ MBC With Brain Metastasis

August 3rd 2021

Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.

Brain Metastasis in HER2+ MBC

August 3rd 2021

Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.

Relapsed/Refractory HER2+ MBC Treatment Decisions

July 27th 2021

Options available to treat patients with HER2-positive metastatic breast cancer following frontline therapy with T-DM1.

Individualized Treatment Decisions for HER2+ Breast Cancer

July 27th 2021

Variables that breast oncologists need to consider when selecting an appropriate systemic treatment approach for a patient with HER2-positive breast cancer.

Subcutaneous Therapy for HER2+ Breast Cancer

July 20th 2021

Breast oncologists discuss the pros and cons of treating patients with HER2-postive breast cancer with the fixed-dose subcutaneous formulation of pertuzumab plus trastuzumab compared with IV chemotherapy.

Safety Profiles of Systemic Therapies for HER2+ MBC

July 20th 2021

Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.

Updates in HER2+ MBC: The NALA and SOPHIA Trials

July 13th 2021

Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.

Implications of DESTINY-Breast01 in HER2+ MBC

July 13th 2021

Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.

The HER2CLIMB Study in HER2+ MBC

July 6th 2021

The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.

Current Standard of Care for HER2+ MBC

July 6th 2021

Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.

Decision Factors for SubQ Therapy and Unmet Needs

March 5th 2021

Phase 3 FeDeriCa and PHranceSCa Trial Overviews

February 26th 2021

Novel Agents for Late-Stage HER2+ MBC

February 26th 2021